Suchergebnisse - "OTT PATRICK"

PubPharm (319)

1

Randomized Placebo-Controlled, Biomarker-Stratified Phase Ib Microbiome Modulation in Melanoma : Impact of Antibiotic Preconditioning on Microbiome and Immunity

enthalten in: Cancer discovery | 2024

von Glitza, I. | Seo, Y. | Spencer, C. | +27

2

Personalized Cancer Vaccines Directed against Tumor Mutations : Building Evidence from Mice to Humans

enthalten in: Cancer research | 2024

von Fritsch, E. | Ott, P.

3

Nivolumab + Tacrolimus + Prednisone ± Ipilimumab for Kidney Transplant Recipients With Advanced Cutaneous Cancers

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024

von Schenk, K. | Deutsch, J. | Chandra, S. | +23

4

Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors

enthalten in: Journal for immunotherapy of cancer | 2024

von Khushalani, N. | Ott, P. | Ferris, R. | +16

5

CORE-SHELL CAPSULES PREPARED WITH LINEAR AND CYCLIC ALIPHATIC POLYISOCYANATES

enthalten in: Europäisches Patentamt | 2024

von OTT PATRICK | BEHRENS KOLJA | EVANS-LORRA TIMOTHY J | +1

6

CORE-SHELL CAPSULES PREPARED WITH LINEAR AND CYCLIC ALIPHATIC POLYISOCYANATES

enthalten in: Europäisches Patentamt | 2024

von OTT PATRICK | BEHRENS KOLJA | EVANS-LORRA TIMOTHY J | +1

7

INDUCE-2 : A Phase I/II, open-label, two-part study of feladilimab in combination with tremelimumab in patients with advanced solid tumors

enthalten in: Cancer immunology, immunotherapy : CII | 2024

von Hilton, J. | Ott, P. | Hansen, A. | +9

8

INDUCE-2: A Phase I/II, open-label, two-part study of feladilimab in combination with tremelimumab in patients with advanced solid tumors

enthalten in: Cancer immunology immunotherapy | 2024

von Hilton, J. | Ott, P. | Hansen, A. | +9

9

Ziv-aflibercept plus pembrolizumab in patients with advanced melanoma resistant to anti-PD-1 treatment

enthalten in: Cancer immunology, immunotherapy : CII | 2024

von Baginska, J. | Nau, A. | Gomez Diaz, I. | +19

10

Ziv-aflibercept plus pembrolizumab in patients with advanced melanoma resistant to anti-PD-1 treatment

enthalten in: Cancer immunology immunotherapy | 2024

von Baginska, J. | Nau, A. | Gomez Diaz, I. | +19

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[32]